在阿德罗普拉斯症中早期新生儿给予沃索里提德:两例病例的报告

相关实验视频

Updated: Mar 12, 2026

05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

61.9K

Shinichiro Sano^1,2, Yuki Murai¹, Kenji Shimizu³

¹Department of Diabetes and Metabolism, Shizuoka Children's Hospital, Shizuoka, Japan.

American journal of medical genetics. Part A

|March 11, 2026

概括

这项研究报告了沃索里提德 (一种C型天然尿素类同类物) 在患有无质形成症 (ACH) 的婴儿中最早使用的情况. 虽然一般耐受性很好,但它并不能防止大门狭窄,这突显了需要进一步研究的需要.

科学领域:

儿科内分泌学儿科内分泌学
骨发育不良症骨发育不良症
药理学药理学是指药理学的学科.

背景情况:

骨质疏松症 (ACH) 是一种影响骨生长的遗传性疾病.
伏索里提德是一种C型天然尿素类型,抑制FGFR3信号传递,已被批准用于ACH治疗.
有限的数据存在于vosoritide在新生儿的使用.

研究的目的:

报告新生儿期开始使用vosoritide的安全性和初步结果.
描述早期接受索治疗的婴儿的生长速度和门狭窄的进展.

主要方法:

两名基因确诊的ACH的婴儿每天接受皮下沃索里提德,从出生后的第8天和第9天开始.
短期安全性,生长速度 (GV) 和连续磁共振成像 (MRI) 监测门狭窄.
对于狭窄的外科减压在9个月和5个月的年龄进行.

主要成果:

在短期监测期间,这两名婴儿都能耐受沃索里提德,没有严重的不良事件.
观察到渐进的巨孔狭窄,这需要在两个病人手术.
增长速度一般保持在ACH特异的中位数以上,并保留了婴儿生长减速.

结论:

在阿孔德罗普拉西亚中,新生儿早期启动索似乎在短期内是安全的,但并没有防止大门狭窄.
这些发现是描述性的和产生假设的,不支持当前临床实践的变化.
需要进一步的数据来确定新生儿沃索里治疗的益处和局限性.

关键词:

这种疾病叫做Achondroplasia.门大狭窄的狭窄这是新生儿新生儿.您可以使用Vosoritide.

相关概念视频

01:29

Drug Dosing: Infants and Children

660

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

660

01:07

Teratogenicity

4.4K

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

4.4K

01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

01:21

Drug Dosing: Obese Patients

325

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

325

01:26

Mitral Stenosis III: Medical Management

404

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

404

01:24

Dosage Regimen: Individualization

250

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

250